Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

The deadliest type of blood cancer is generally considered to be acute myeloid leukemia (AML). AML has a survival rate of 31.7% overall, though children and adolescents under the age of 15 tend to do ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

One such type is Acute Lymphoblastic Leukemia (ALL), which is characterised ... to understand its symptoms, survival rates, life expectancy, and treatment options available to those affected.

KU School of Medicine-Wichita Department of Pediatrics and Wesley Children’s Hospital say a groundbreaking treatment for ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

31.9% Acute myeloid leukemia (AML) has a 31.9% five-year survival rate. Leukemia is a broad term for cancers caused by the development of mutations in stem cells in the bone marrow, which would ...

Leukemia can broadly be categorized as being acute or chronic. Each can manifest with different symptoms and at different rates. Acute leukemia is caused when blood stem cells fail to mature into ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.